Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) fell 7% during mid-day trading on Wednesday . The company traded as low as $0.62 and last traded at $0.65. 5,439,270 shares changed hands during trading, an increase of 265% from the average session volume of 1,492,054 shares. The stock had previously closed at $0.70.
Several hedge funds have recently bought and sold shares of AMPE. Rhumbline Advisers acquired a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $154,000. Valeo Financial Advisors LLC acquired a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $155,000. Courier Capital LLC raised its position in shares of Ampio Pharmaceuticals by 2,032.7% during the 3rd quarter. Courier Capital LLC now owns 304,973 shares of the specialty pharmaceutical company’s stock worth $155,000 after purchasing an additional 290,673 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Ampio Pharmaceuticals during the 3rd quarter worth approximately $220,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $326,000.
Ampio Pharmaceuticals Company Profile (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Further Reading: Market Capitalization